Annals of Surgical Oncology

, Volume 17, Issue 10, pp 2720–2727 | Cite as

Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin Versus Cisplatin

  • Aaron U. Blackham
  • Perry Shen
  • John H. Stewart
  • Gregory B. Russell
  • Edward A. Levine
Gastrointestinal Oncology



Malignant peritoneal mesothelioma (MPM) is a rare, rapidly fatal disease. Because traditional treatments offer little benefit, there has been increasing interest in cytoreductive surgery (CS) with intraperitoneal hyperthermic chemotherapy (IPHC). The most efficacious chemotherapy regimen is not established. Herein we report clinical outcomes of MPM patients treated with CS and IPHC and contrast results using two chemoperfusates: mitomycin and cisplatin.


Thirty-four patients were treated for MPM. Following CS, 19 patients underwent IPHC with mitomycin and 15 received cisplatin. Overall survival, disease-free survival, and progression-free survival were compared between the two groups.


Overall survival was 56 and 17% at 3 and 5 years, with median survival of 40.8 months. Those perfused with cisplatin were more likely to be alive at 1, 2, and 3 years (P < 0.05, 0.05, and 0.04, respectively). Median survival for mitomycin and cisplatin was 10.8 and 40.8 months, respectively (P = 0.22). Median disease-free survival and progression-free survival were 10.3 and 9.1 months, respectively. There was a trend toward improved disease-free and progression-free survival using cisplatin.


CS with IPHC is a promising modality for patients with MPM, and clinical outcomes appear to be improved using cisplatin. We recommend using high-dose intraperitoneal cisplatin following cytoreductive surgery when treating malignant peritoneal mesothelioma.


Mitomycin Malignant Mesothelioma Intraperitoneal Chemotherapy Complete Cytoreduction Intraperitoneal Hyperthermic Chemotherapy 


  1. 1.
    Sridhar K, Doria R, Raub W, Thurer R, Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer. 1992;70:2969–2979.CrossRefPubMedGoogle Scholar
  2. 2.
    Wagner J, Sleggs C, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–271.PubMedGoogle Scholar
  3. 3.
    Robinson B, Lake R. Advances in Malignant Mesothelioma. NEJM. 2005;353:1591–1603.CrossRefPubMedGoogle Scholar
  4. 4.
    Chailleux E, Dabouis G, Pioche D, de Lajartre M, de Lajartre A, Rembeaus A, et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest. 1988;93:159–162.CrossRefPubMedGoogle Scholar
  5. 5.
    Pass H, Kranda K, Temeck B, Feuerstein I, Steinberg S. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol. 1997;4:215–222.CrossRefPubMedGoogle Scholar
  6. 6.
    Janne P. Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer. 2003;5:98–106.CrossRefPubMedGoogle Scholar
  7. 7.
    Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol. 1988;6:147–153.PubMedGoogle Scholar
  8. 8.
    Ribak J, Lilus R, Suzuki Y, Penner L, Selikoff I. Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and cause of death. Br J Ind Med. 1998;45:182–187.Google Scholar
  9. 9.
    Loggie B, Fleming R, MeQuellon R, Russell G, Geisinger K, Levine E. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67:999–1003.PubMedGoogle Scholar
  10. 10.
    Park B, Alexander H, Libutti S, Wu P, Royalty D, Kranda K, Bartlett D. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion. Ann Surg Oncol. 1999;6:582–590.CrossRefPubMedGoogle Scholar
  11. 11.
    Loggie B, Fleming R, McQuellon R, Russell G, Geisinger K. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg. 2000;66:561–568.PubMedGoogle Scholar
  12. 12.
    Howell S, Pfeifle C, Wung W, Olshen R, Lucas W, Yon J, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97:845–851.PubMedGoogle Scholar
  13. 13.
    Leitao D, Blakley B. Quantification of sodium thiosulfate protection on cisplatin-induced toxicities. J Otolaryngol. 2003;32:146–150.CrossRefPubMedGoogle Scholar
  14. 14.
    Common Terminology Criteria for Adverse Events (CTCAE). Version 3.0. Published June 10, 2003.Google Scholar
  15. 15.
    Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229–237.CrossRefPubMedGoogle Scholar
  16. 16.
    Yan T, Brun E, Cerruto C, Haveric N, Chang D, Sugarbaker P. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41–49.CrossRefPubMedGoogle Scholar
  17. 17.
    Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated with locoregionally at a single institution. Cancer. 2005;104:2181–2188.CrossRefPubMedGoogle Scholar
  18. 18.
    Cerruto C, Brun E, Dhang D, Sugarbaker P. Prognostic Significance of Histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. 2006;130:1654–1661.PubMedGoogle Scholar
  19. 19.
    Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard A, Isaac S, Gilly F, et al. Peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13:405–412.CrossRefPubMedGoogle Scholar
  20. 20.
    Yan T, Welch L, Black D, Sugarbaker P. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827–834.CrossRefPubMedGoogle Scholar
  21. 21.
    Feldman A, Libutti S, Pingpank J, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–4567.CrossRefPubMedGoogle Scholar
  22. 22.
    Hesdorffer M, Chabot J, Keohan M, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008;31;49–54.CrossRefPubMedGoogle Scholar
  23. 23.
    Levine E, Stewart J, Russell G, Geisinger K, Loggie B, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 patients. J Am Coll Surg. 2007;204:943–53.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2010

Authors and Affiliations

  • Aaron U. Blackham
    • 1
  • Perry Shen
    • 1
  • John H. Stewart
    • 1
  • Gregory B. Russell
    • 2
  • Edward A. Levine
    • 1
  1. 1.Surgical Oncology ServiceWake Forest University Baptist Medical CenterWinston-SalemUSA
  2. 2.Departments of General Surgery and Public Health SciencesWake Forest University Baptist Medical CenterWinston-SalemUSA

Personalised recommendations